File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: A randomized placebo controlled double blind trial of augmentation of clozapine with risperidone

TitleA randomized placebo controlled double blind trial of augmentation of clozapine with risperidone
Authors
Issue Date2005
PublisherOxford University Press. The Journal's web site is located at http://schizophreniabulletin.oxfordjournals.org/
Citation
The 20th International Congress on Schizophrenia Research, Savannah, GA., 2-6 April 2005. In Schizophrenia Bulletin, 2005, v. 31 n. 2, p. 487 How to Cite?
AbstractIncomplete or partial improvement of symptoms following treatment with clozapine is not infrequent in chronic schizophrenia. Commonly, patients are prescribed an additional antipsychotic medication, although there is little evidence from controlled studies of the efficacy of this practice. We performed a placebo controlled study of risperidone augmentation of partial response to clozapine in schizophrenia. Subjects were required to be treated with clozapine at a stable dose of 400 mg or more for at least 12 weeks prior to screening. Concurrent psychotropic medications were discontinued at least 2 weeks prior to study entry. At baseline (on clozapine), the total PANSS score was 97.1 (n=69), and following one week of placebo augmentation run-in the total PANSS score was 99.6. Subjects were randomized to continuation of clozapine+placebo, or to clozapine+risperidone 3.0 mg for 8 weeks. Clozapine doses were unchanged. The study completion rate was 94% (n=65). Using a last observation carried forward approach, the total PANSS score at the end of the double blind phase was 87.7- there were no statistically significant differences between the placebo- and the risperidone augmentation groups. According to a 20% decline in total PANSS score approach to categorize subjects as responders, the rates of response were 26% (n=9/35) in the placebo augmentation group, and 18% (6/34) in the risperidone augmentation group. Addition of the requirement of a CGI score of 3 or less to define treatment response resulted in a rate of 11% (4/35) in the placebo augmentation group, and 3% (1/34) in the risperidone augmentation group. Addition of risperidone to clozapine does not appear to offer significant advantages in reducing the symptoms of schizophrenia in patients with poor or incomplete response to clozapine alone. Supported by the Stanley Medical Research Institute.
DescriptionThis journal issue entitled: Special Issue: Abstracts of the XX International Congress on Schizophrenia Research
Persistent Identifierhttp://hdl.handle.net/10722/105341
ISSN
2015 Impact Factor: 7.757
2015 SCImago Journal Rankings: 4.051

 

DC FieldValueLanguage
dc.contributor.authorHoner, Wen_HK
dc.contributor.authorEacEwan, GWen_HK
dc.contributor.authorWilliams, Ren_HK
dc.contributor.authorFalkai, Pen_HK
dc.contributor.authorMcKenna, PJen_HK
dc.contributor.authorClotet, Pen_HK
dc.contributor.authorChen, EYHen_HK
dc.contributor.authorLeung, SPen_HK
dc.contributor.authorWong, JGWSen_HK
dc.contributor.authorStip, Een_HK
dc.date.accessioned2010-09-25T22:30:08Z-
dc.date.available2010-09-25T22:30:08Z-
dc.date.issued2005en_HK
dc.identifier.citationThe 20th International Congress on Schizophrenia Research, Savannah, GA., 2-6 April 2005. In Schizophrenia Bulletin, 2005, v. 31 n. 2, p. 487en_HK
dc.identifier.issn0586-7614en_HK
dc.identifier.urihttp://hdl.handle.net/10722/105341-
dc.descriptionThis journal issue entitled: Special Issue: Abstracts of the XX International Congress on Schizophrenia Research-
dc.description.abstractIncomplete or partial improvement of symptoms following treatment with clozapine is not infrequent in chronic schizophrenia. Commonly, patients are prescribed an additional antipsychotic medication, although there is little evidence from controlled studies of the efficacy of this practice. We performed a placebo controlled study of risperidone augmentation of partial response to clozapine in schizophrenia. Subjects were required to be treated with clozapine at a stable dose of 400 mg or more for at least 12 weeks prior to screening. Concurrent psychotropic medications were discontinued at least 2 weeks prior to study entry. At baseline (on clozapine), the total PANSS score was 97.1 (n=69), and following one week of placebo augmentation run-in the total PANSS score was 99.6. Subjects were randomized to continuation of clozapine+placebo, or to clozapine+risperidone 3.0 mg for 8 weeks. Clozapine doses were unchanged. The study completion rate was 94% (n=65). Using a last observation carried forward approach, the total PANSS score at the end of the double blind phase was 87.7- there were no statistically significant differences between the placebo- and the risperidone augmentation groups. According to a 20% decline in total PANSS score approach to categorize subjects as responders, the rates of response were 26% (n=9/35) in the placebo augmentation group, and 18% (6/34) in the risperidone augmentation group. Addition of the requirement of a CGI score of 3 or less to define treatment response resulted in a rate of 11% (4/35) in the placebo augmentation group, and 3% (1/34) in the risperidone augmentation group. Addition of risperidone to clozapine does not appear to offer significant advantages in reducing the symptoms of schizophrenia in patients with poor or incomplete response to clozapine alone. Supported by the Stanley Medical Research Institute.-
dc.languageengen_HK
dc.publisherOxford University Press. The Journal's web site is located at http://schizophreniabulletin.oxfordjournals.org/en_HK
dc.relation.ispartofSchizophrenia Bulletinen_HK
dc.rightsSchizophrenia Bulletin. Copyright © Oxford University Press.en_HK
dc.titleA randomized placebo controlled double blind trial of augmentation of clozapine with risperidoneen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0586-7614&volume=31&spage=487&epage=&date=2005&atitle=A+randomized+placebo+controlled+double+blind+trial+of+augmentation+of+clozapine+with+risperidoneen_HK
dc.identifier.emailChen, EYH: eyhchen@hku.hken_HK
dc.identifier.emailWong, JGWS: jgwswong@hkucc.hku.hken_HK
dc.identifier.doi10.1093/schbul/sbi024-
dc.identifier.hkuros103298en_HK
dc.identifier.volume31en_HK
dc.identifier.issue2-
dc.identifier.spage487en_HK
dc.identifier.epage487-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats